- Home
- ZBH vs GMAB Comparison
ZBH vs GMAB Comparison
Compare ZBH & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBH
- GMAB
- Stock Information
- Founded
- ZBH 1927
- GMAB 1999
- Country
- ZBH United States
- GMAB Denmark
- Employees
- ZBH N/A
- GMAB N/A
- Industry
- ZBH Industrial Specialties
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ZBH Health Care
- GMAB Health Care
- Exchange
- ZBH Nasdaq
- GMAB Nasdaq
- Market Cap
- ZBH 19.9B
- GMAB 17.4B
- IPO Year
- ZBH N/A
- GMAB N/A
- Fundamental
- Price
- ZBH $88.48
- GMAB $29.01
- Analyst Decision
- ZBH Buy
- GMAB Strong Buy
- Analyst Count
- ZBH 19
- GMAB 6
- Target Price
- ZBH $108.56
- GMAB $40.40
- AVG Volume (30 Days)
- ZBH 2.2M
- GMAB 2.6M
- Earning Date
- ZBH 11-05-2025
- GMAB 11-06-2025
- Dividend Yield
- ZBH 1.08%
- GMAB N/A
- EPS Growth
- ZBH N/A
- GMAB 132.41
- EPS
- ZBH 4.03
- GMAB 25.10
- Revenue
- ZBH $8,010,900,000.00
- GMAB $3,845,670,022.00
- Revenue This Year
- ZBH $8.20
- GMAB $24.92
- Revenue Next Year
- ZBH $5.92
- GMAB $15.97
- P/E Ratio
- ZBH $22.00
- GMAB $1.16
- Revenue Growth
- ZBH 5.47
- GMAB 29.57
- 52 Week Low
- ZBH $85.33
- GMAB $17.24
- 52 Week High
- ZBH $114.72
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- ZBH 31.07
- GMAB 46.20
- Support Level
- ZBH $85.33
- GMAB $28.08
- Resistance Level
- ZBH $90.16
- GMAB $29.35
- Average True Range (ATR)
- ZBH 2.96
- GMAB 0.65
- MACD
- ZBH -1.60
- GMAB -0.20
- Stochastic Oscillator
- ZBH 14.01
- GMAB 50.81
About ZBH Zimmer Biomet Holdings Inc.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.